podcast | pharmaphorum

Skip to main content

Wednesday 20 May 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

podcast

Oncology

pharmaphorum podcast Episode 196a, Dr Corina Dutcus

Putting patients and their families first: Dr Corina Dutcus,...

Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, discusses the data Eisai presented at ASCO 2025.

Oncology

pharmaphorum podcast Episode 195a - Dan Schmitt, Actuate

Enhancing anti-tumour activity: A post-ASCO conversation wit...

Market Access

happy man listening to podcast

Why Datavant bought Aetion, and what comes next, with Arnaub...

Digital

pharmaphorum podcast Episode 193a, Pamela Tenaerts, Medable

Post-ASCO 25: Pamela Tenaerts on CGTs and digital-first long...

In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable.

R&D

pharmaphorum podcast Episode 192a

Immune mediation, B-cell depletion, and female leadership – ...

In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases.

R&D

pharmaphorum podcast Episode 191a, Ben Sidders

Ben Sidders on integrating causality in AI for R&D success

Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.

Load more results

Editor's Picks

'Seismic shift' as obesity overtakes cancer for R&D returns

Bayer returns to M&A with $2.45bn Perfuse Therapeutics deal

Lilly inflates US facility investment spending by $4.5bn

Roche buys AI-powered diagnostics player PathAI

Danco fights back after US court curbs abortion pill access

News

Remepy's hybrid Parkinson's therapy poised for phase 3

Remepy's hybrid Parkinson's therapy poised for phase 3

Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company